Brief: Cambridge Cognition Says Monument Therapeutics Achieves Positive Phase I Results For Novel Schizophrenia Treatment
24/06/2025 07:44
June 24 (Reuters) - Cambridge Cognition Holdings PLC COGC.L: CAMBRIDGE COGNITION: MONUMENT THERAPEUTICS ACHIEVES POSITIVE PHASE I RESULTS FOR NOVEL SCHIZOPHRENIA TREATMENT Source text: ID:nRSX0554Oa Further company coverage: COGC.L ((( Reuters.Briefs@thomsonreuters.com );))
Recent news on Cambridge Cognition Holdings
See all newsRCS - Cambridge Cognition - COG joins Imperial College-led NHS Study
Cambridge Cognition - Director/PDMR Share Purchases
RCS - Cambridge Cognition - Partnership with C2N and The Alzheimer's Trust
Brief: Cambridge Cognition Sees Annual Revenue Not Less Than £10 Mln
UK's Cambridge Cognition H1 revenue rises 16%, debt repaid